文献速递间质性肺疾病

药物诱导的间质性肺疾病

Drug-induced interstitial lung disease.
PubMed 文献 · Eur Respir J · 2022-10-27

药物诱导性肺损伤所致的间质性肺疾病(DI-ILD)是日益常见的致病和致死原因,涉及化疗药、分子靶向药、免疫检查点抑制剂、抗生素、抗心律失常药及传统或生物改善病情抗风湿药等。DI-ILD临床表现多样,从轻微呼吸道症状到快速进展的呼吸衰竭和死亡均可出现。多数病例缺乏特征性临床、实验室、影像或病理表现,诊断需结合已知肺毒性药物暴露史并排除其他原因。早期识别并永久停用致病药物是治疗基石,致残性或进展性疾病患者使用全身糖皮质激素;对检查点抑制剂等特定药物需采取预防策略,且发生DI-ILD不一定意味着永久停药。

要点

  • DI-ILD诊断需有已知肺毒性药物暴露并排除其他间质性肺疾病原因。
  • 早期识别并永久停用致病药物是治疗基石。
  • 致残性或进展性疾病患者使用全身糖皮质激素。

核心结论

  • 药物诱导的间质性肺疾病是日益常见的致病和致死原因,早期识别并停用致病药物是治疗核心。

主要发现

  • 与间质性肺疾病相关的药物数量持续增加,主要因肿瘤和风湿病领域使用新型单克隆抗体和生物制剂。
  • DI-ILD临床表现多样,从轻微呼吸道症状到快速进展的呼吸衰竭和死亡均可发生。
  • 多数病例缺乏特征性临床、实验室、影像或病理特征。

关键数值与推荐

  • 诊断DI-ILD需存在已知致肺毒性药物暴露,并排除其他间质性肺疾病原因。
  • 致残性或进展性疾病患者使用全身糖皮质激素。
  • 对检查点抑制剂等特定药物需采取预防策略,发生DI-ILD不一定意味着永久停药,尤其在缺乏有效治疗替代时。

临床怎么用

  • 对有已知肺毒性药物暴露且怀疑间质性肺疾病的患者,应排除其他原因并尽早识别DI-ILD。
  • 确诊后永久停用致病药物;对致残性或进展性疾病使用全身糖皮质激素。
  • 对检查点抑制剂等特定药物,应实施预防策略,并根据有无有效治疗替代决定是否永久停药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Interstitial lung disease (ILD) secondary to drug-induced lung injury is an increasingly common cause of morbidity and mortality. The number of drugs associated with the development of ILD continues to rise, mainly due to the use of novel monoclonal antibodies and biologicals for neoplastic and rheumatological diseases, and includes, among others, chemotherapeutics, molecular targeting agents, immune checkpoint inhibitors, antibiotics, antiarrhythmics and conventional or biological disease-modifying antirheumatic drugs. Drug-induced ILD (DI-ILD) manifests with a variety of clinical patterns, ranging from mild respiratory symptoms to rapidly progressive respiratory failure and death. In most cases, there are no pathognomonic clinical, laboratory, radiological or pathological features and the diagnosis of DI-ILD is suspected in the presence of exposure to a drug known to cause lung toxicity and after exclusion of alternative causes of ILD. Early identification and permanent discontinuation of the culprit drug are the cornerstones of treatment with systemic glucocorticoids being used in patients with disabling or progressive disease. However, for certain drugs, such as checkpoint inhibitors, the frequency of lung toxicity is such that mitigation strategies are put in place to prevent this complication, and occurrence of DI-ILD is not necessarily synonymous with permanent drug discontinuation, particularly in the absence of valid therapeutic alternatives.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Spagnolo P, Bonniaud P, Rossi G, et al. Drug-induced interstitial lung disease. Eur Respir J. 2022. PMID: 35332071. doi:10.1183/13993003.02776-2021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。